MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF)…
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to…
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:…
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
MitoSynergy Introduces BioCopper1 – A Clinically Proven Nutraceutical Designed for Mitochondrial Performance
Scottsdale, AZ, March 24, 2026 (GLOBE NEWSWIRE) -- MitoSynergy, a science-driven wellness…
BioSyent Announces Grant of Restricted Share Units
March 24, 2026 17:30 ET | Source: BioSyent Inc. MISSISSAUGA, Ontario, March…
Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Approval in moderate-to-severe patients was based on pivotal trial results showing over…
Idorsia announces the nomination of three candidates for election to the Board of Directors
Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial…
Press Release: Sanofi and Regenerons Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine…
